$25.40
2.46% yesterday
Nasdaq, Sep 11, 10:00 pm CET
ISIN
US03753U1060
Symbol
APLS

Apellis Pharmaceuticals, Inc. Stock price

$25.40
+1.55 6.50% 1M
-0.12 0.47% 6M
-6.51 20.40% YTD
-12.96 33.79% 1Y
-41.87 62.24% 3Y
-3.26 11.37% 5Y
+11.37 81.04% 10Y
+11.37 81.04% 20Y
Nasdaq, Closing price Thu, Sep 11 2025
-0.64 2.46%
ISIN
US03753U1060
Symbol
APLS
Industry

Key metrics

Basic
Market capitalization
$3.2b
Enterprise Value
$3.3b
Net debt
$84.0m
Cash
$370.0m
Shares outstanding
126.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.3 | 3.4
EV/Sales
4.4 | 3.5
EV/FCF
746.4
P/B
20.5
Financial Health
Equity Ratio
25.8%
Return on Equity
-86.6%
ROCE
-30.6%
ROIC
-
Debt/Equity
2.9
Financials (TTM | estimate)
Revenue
$754.7m | $942.2m
EBITDA
$-188.3m | $-103.7m
EBIT
$-190.1m | $-45.6m
Net Income
$-228.2m | $-99.7m
Free Cash Flow
$4.4m
Growth (TTM | estimate)
Revenue
20.0% | 20.6%
EBITDA
39.5% | 36.5%
EBIT
39.3% | 72.3%
Net Income
31.5% | 49.6%
Free Cash Flow
101.1%
Margin (TTM | estimate)
Gross
83.8%
EBITDA
-25.0% | -11.0%
EBIT
-25.2%
Net
-30.2% | -10.6%
Free Cash Flow
0.6%
More
EPS
$-1.8
FCF per Share
$0.0
Short interest
21.4%
Employees
708
Rev per Employee
$1.1m
Show more

Is Apellis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Apellis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:

18x Buy
67%
9x Hold
33%

Analyst Opinions

27 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Apellis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
755 755
20% 20%
100%
- Direct Costs 122 122
43% 43%
16%
632 632
16% 16%
84%
- Selling and Administrative Expenses 504 504
8% 8%
67%
- Research and Development Expense 318 318
2% 2%
42%
-188 -188
40% 40%
-25%
- Depreciation and Amortization 1.80 1.80
2% 2%
0%
EBIT (Operating Income) EBIT -190 -190
39% 39%
-25%
Net Profit -228 -228
31% 31%
-30%

In millions USD.

Don't miss a Thing! We will send you all news about Apellis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apellis Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Baird Global Healthcare Conference September 9, 2025 10:15 AM EDT Company Participants Cedric Francois - Co-Founder, President, CEO & Director Timothy Sullivan - CFO & Treasurer Conference Call Participants Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Presentation Colleen Hanley Senior Research Analyst Right.
Neutral
Seeking Alpha
8 days ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Cantor Global Healthcare Conference 2025 September 4, 2025 8:35 AM EDT Company Participants Cedric Francois - Co-Founder, President, CEO & Director Timothy Sullivan - CFO & Treasurer Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst [Audio Gap] Would lov...
Neutral
Seeking Alpha
9 days ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:45 AM EDT Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Executive Vice President of Commercial Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone...
More Apellis Pharmaceuticals, Inc. News

Company Profile

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Head office United States
CEO Cedric Francois
Employees 708
Founded 2009
Website apellis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today